文献
J-GLOBAL ID:202002248094739550
整理番号:20A2635522
バイオシミラーの互換性:米国における互換性指定をサポートするために臨床証拠のレベルは必要か?【JST・京大機械翻訳】
Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
著者 (6件):
Alvarez Daniel F.
(Inflammation and Immunology, Pfizer Inc, Collegeville, PA, USA)
,
Wolbink Gertjan
(University of Amsterdam, Amsterdam, The Netherlands)
,
Cronenberger Carol
(Clinical Pharmacology, Pfizer Inc, Collegeville, PA, USA)
,
Orazem John
(Global Biostatistics and Data Management, Pfizer Inc, New York, NY, USA)
,
Kay Jonathan
(Departments of Medicine and of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA)
,
Kay Jonathan
(Department of Medicine, UMass Memorial Medical Center, Worcester, MA, USA)
資料名:
BioDrugs
(BioDrugs)
巻:
34
号:
6
ページ:
723-732
発行年:
2020年
JST資料番号:
W0641A
ISSN:
1173-8804
資料種別:
逐次刊行物 (A)
記事区分:
文献レビュー
発行国:
ドイツ (DEU)
言語:
英語 (EN)